The University of Chicago Header Logo

Connection

George Bakris to Animals

Back to Details
This is a "connection" page, showing publications George Bakris has written about Animals.
George Bakris
Connection Strength
0.871
Animals
  1. The changing trajectory of diabetic kidney disease. Curr Opin Nephrol Hypertens. 2023 01 01; 32(1):98-102.
    View in: PubMed
    Score: 0.056
  2. Novel antihypertensive agents for resistant hypertension: what does the future hold? Hypertens Res. 2022 12; 45(12):1918-1928.
    View in: PubMed
    Score: 0.056
  3. Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease. Clin Pharmacol Ther. 2017 Sep; 102(3):450-458.
    View in: PubMed
    Score: 0.039
  4. Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol. 2015 Apr; 21:20-4.
    View in: PubMed
    Score: 0.033
  5. The future of renal denervation in resistant hypertension. Curr Hypertens Rep. 2014 Dec; 16(12):494.
    View in: PubMed
    Score: 0.033
  6. Sympathetic activation in resistant hypertension: theory and therapy. Semin Nephrol. 2014; 34(5):550-9.
    View in: PubMed
    Score: 0.031
  7. Metformin nephrotoxicity insights: will they change clinical management? J Diabetes. 2014 Mar; 6(2):111-2.
    View in: PubMed
    Score: 0.031
  8. Efficacy of baroreflex activation therapy for the treatment of resistant hypertension. EuroIntervention. 2013 May; 9 Suppl R:R136-9.
    View in: PubMed
    Score: 0.029
  9. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2010 Nov; 28(4):545-59.
    View in: PubMed
    Score: 0.025
  10. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010 Nov; 11(16):2675-86.
    View in: PubMed
    Score: 0.024
  11. More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors. J Hypertens. 2010 Jul; 28(7):1382-3.
    View in: PubMed
    Score: 0.024
  12. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009 Jun; 75(12):1272-1277.
    View in: PubMed
    Score: 0.022
  13. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2009 Mar; 18(2):107-11.
    View in: PubMed
    Score: 0.022
  14. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des. 2009; 15(5):529-36.
    View in: PubMed
    Score: 0.022
  15. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008 Aug; 4(8):444-52.
    View in: PubMed
    Score: 0.021
  16. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int. 2008 Apr; 73(7):795-6.
    View in: PubMed
    Score: 0.020
  17. The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance? Am J Nephrol. 2007; 27(1):44-54.
    View in: PubMed
    Score: 0.019
  18. Review: Insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab. 2007 Feb; 92(2):379-85.
    View in: PubMed
    Score: 0.019
  19. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006 Dec; 70(11):1905-13.
    View in: PubMed
    Score: 0.018
  20. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006 Oct; 70(7):1223-33.
    View in: PubMed
    Score: 0.018
  21. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens. 2004 Dec; 17(12 Pt 2):23S-30S.
    View in: PubMed
    Score: 0.016
  22. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun; 65(6):1991-2002.
    View in: PubMed
    Score: 0.016
  23. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022 05 25; 37(6):1014-1023.
    View in: PubMed
    Score: 0.014
  24. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002 Feb; 7(1):35-43.
    View in: PubMed
    Score: 0.013
  25. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. Kidney Int. 1999 Jul; 56(1):206-10.
    View in: PubMed
    Score: 0.011
  26. The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab. 1998; 24(6):381-8.
    View in: PubMed
    Score: 0.010
  27. Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. Kidney Int Suppl. 1997 Dec; 63:S67-70.
    View in: PubMed
    Score: 0.010
  28. Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. J Diabetes Complications. 1997 Nov-Dec; 11(6):352-7.
    View in: PubMed
    Score: 0.010
  29. Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant. 1997 Nov; 12(11):2244-50.
    View in: PubMed
    Score: 0.010
  30. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens. 1997 Oct; 15(10):1181-5.
    View in: PubMed
    Score: 0.010
  31. Renal components of the hypertensive syndrome. J Cardiovasc Risk. 1997 Aug; 4(4):271-7.
    View in: PubMed
    Score: 0.010
  32. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens. 1997 Jan; 11(1):35-8.
    View in: PubMed
    Score: 0.009
  33. Is the level of arterial pressure reduction important for preservation of renal function. Nephrol Dial Transplant. 1996 Dec; 11(12):2383-4.
    View in: PubMed
    Score: 0.009
  34. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016 07; 2(3):200-5.
    View in: PubMed
    Score: 0.009
  35. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995 Oct; 10 Suppl 9:56-62.
    View in: PubMed
    Score: 0.009
  36. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens Suppl. 1995 Aug; 13(2):S95-101.
    View in: PubMed
    Score: 0.009
  37. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol. 1995 Jan; 35(1):73-80.
    View in: PubMed
    Score: 0.008
  38. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 1994 Jul; 46(1):161-9.
    View in: PubMed
    Score: 0.008
  39. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol. 2014; 39(6):499-508.
    View in: PubMed
    Score: 0.008
  40. Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol. 1994; 23 Suppl 1:S34-8.
    View in: PubMed
    Score: 0.008
  41. Diabetic nephropathy. Dis Mon. 1993 Aug; 39(8):573-611.
    View in: PubMed
    Score: 0.007
  42. Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. Hypertension. 2013 Sep; 62(3):444-9.
    View in: PubMed
    Score: 0.007
  43. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993 Jun; 43(6):1210-8.
    View in: PubMed
    Score: 0.007
  44. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med. 1993 Apr 15; 118(8):643-4.
    View in: PubMed
    Score: 0.007
  45. Hypertension in diabetic patients. An overview of interventional studies to preserve renal function. Am J Hypertens. 1993 Apr; 6(4):140S-147S.
    View in: PubMed
    Score: 0.007
  46. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013 Sep 01; 167(5):1677-87.
    View in: PubMed
    Score: 0.007
  47. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012 Nov; 33(22):2782-95.
    View in: PubMed
    Score: 0.007
  48. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease. Arch Intern Med. 1991 Dec; 151(12):2367-72.
    View in: PubMed
    Score: 0.007
  49. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states. J Am Soc Nephrol. 1991 Aug; 2(2 Suppl 1):S21-9.
    View in: PubMed
    Score: 0.006
  50. Renal effects of calcium antagonists in diabetes mellitus. An overview of studies in animal models and in humans. Am J Hypertens. 1991 Jul; 4(7 Pt 2):487S-493S.
    View in: PubMed
    Score: 0.006
  51. Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium. Radiology. 1990 Apr; 175(1):57-60.
    View in: PubMed
    Score: 0.006
  52. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990 Jan; 258(1 Pt 2):F115-20.
    View in: PubMed
    Score: 0.006
  53. Does dietary salt increase the risk for progression of kidney disease? Curr Hypertens Rep. 2005 Oct; 7(5):385-91.
    View in: PubMed
    Score: 0.004
  54. A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int. 1985 Feb; 27(2):465-8.
    View in: PubMed
    Score: 0.004
  55. Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis. 2002 May; 39(5):899-919.
    View in: PubMed
    Score: 0.003
  56. Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension. 2001 May; 37(5):1268-72.
    View in: PubMed
    Score: 0.003
  57. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000 Apr; 57(4):1651-61.
    View in: PubMed
    Score: 0.003
  58. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999 May; 55(5):1849-60.
    View in: PubMed
    Score: 0.003
  59. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med. 1987 Oct; 110(4):406-11.
    View in: PubMed
    Score: 0.001
  60. A liquid chromatographic assay for 5-hydroxytryptophan, serotonin and 5-hydroxyindoleacetic acid in human body fluids. Acta Pharmacol Toxicol (Copenh). 1982 Nov; 51(5):421-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.